Drug details

Zelboraf (vemurafenib)

type of Antineoplastics BRAF Kinase Inhibitor

Zelboraf (vemurafenib) is a kinase inhibitor used to treat patients with metastatic melanoma with BRAFV600E mutation that is unable to be removed by surgery.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• nausea,
• loss of appetite,
• vomiting,
• fever,
• swollen glands,
• shortness of breath,
• fluttering in your chest,
• muscle aches,
• sore throat,
• skin pain,
• stomach pain (upper right side),
• dark urine, and
• vision changes,
• fast or pounding heartbeats,
• sudden dizziness,
• burning in your eyes,
• eye pain or swelling,
• severe weakness,
• unusual bruising,
• yellowing of your skin or eyes (jaundice),
• red or purple skin rash that spreads and causes blistering and peeling,
• clay-colored stools
• small white or yellow patches on the surface of your eye,
• severe eye redness,
• a new wart or lesion,
• skin sore or red bump that bleeds or does not heal,
• any change in the size or color of a mole,
• unusual thickening of tissues under the skin on the palms of your hands or the soles of your feet,
• finger or fingers that feel tight or are bent inward,

The following drugs are related to Zelboraf, either as a replacement or used together:

• Proleukin (aldesleukin for injection)
• Mektovi (binimetinib tablets)
• Braftovi (encorafenib capsules)
• Cotellic (cobimetinib tablets)
• Kimmtrak (tebentafusp-tebn injection, for intravenous use)
• Opdualag (nivolumab and relatlimab-rmbw injection)
• Opdivo (nivolumab injection)